LifeSci Capital Initiates a Buy Rating on Zymeworks (ZYME)
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
Lifesci Capital Has Pessimistic View of ATXS FY2025 Earnings
Stock analysts at Lifesci Capital cut their FY2025 earnings per share estimates for Astria Therapeutics in a research report ...
Protara Therapeutics (TARA) Has a New Rating from LifeSci Capital
In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Protara Therapeutics (TARA – Research ...
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital
Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...
Fintel on MSN6d
LifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform Recommendation
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Immunome (NasdaqCM:IMNM) with a Outperform ...
Fintel on MSN5d
LifeSci Capital Initiates Coverage of Molecular Partners AG - Depositary Receipt () (MOLN) with Outperform Recommendation
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Molecular Partners AG - Depositary Receipt () ...
Nasdaq13d
LifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform Recommendation
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a Outperform recommendation. As of March 4, 2025, the average one-year price ...
Wall Street Journal1mon
Virtus LifeSci Biotech Products ETF
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. The Index seeks to track the ...
Nasdaq13d
LifeSci Capital Initiates Coverage of Molecular Partners AG - Depositary Receipt () (MOLN) with Outperform Recommendation
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Molecular Partners AG - Depositary Receipt () (NasdaqGS:MOLN) with a Outperform recommendation. As of March 4 ...